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Summary In vivo models of acquired resistance to the platinum-based agents cisplatin (CDDP), carboplatin
(CBDCA), iproplatin (CHIP) and tetraplatin have been established using a panel of six parent human ovarian
carcinoma lines, two (HX/I 10 and PXN/87) being derived from previously untreated patients. Resistance has
been generated to CDDP (three lines), CBDCA (one line), CHIP (three lines) and tetraplatin (one line) either
by treatment in vivo or (for one line to CDDP) through exposure in vitro and subsequent transfer to mice.
With the four tumours where resistance was generated using CDDP or CBDCA, a complete cross-resistance to
the remaining platinum agents studied was observed. In contrast, in one of three lines with derived resistance
to the platinum (IV) agent, CHIP, (PXN/951) a retention in sensitivity was observed with CDDP and
CBDCA. Only one of the six parent tumour lines (PXN/100) was markedly sensitive to tetraplatin. Where
resistance was generated to tetraplatin (PXN/100T) there was some retention of activity by CDDP. For the
CDDP-resistant line established in vitro, there was a close agreement between the cross-resistance profile
obtained in vitro vs that obtained in vivo. This tumour panel may be useful in the elucidation of cellular and
molecular resistance mechanisms to platinum drugs operative in vivo. Moreover, as they appear to mimic the
clinical observations of shared cross-resistance between CDDP, CBDCA and CHIP, they may represent
valuable preclinical evaluation models for the discovery of drugs capable of conferring responses in CDDP-
refractory ovarian cancer.
In addition to primary resistance, the acquisition of tumour
resistance to the platinum-based drugs cisplatin and carbo-
platin often results in unsuccessful treatment outcome. This is
particularly the case for advanced ovarian cancer, where
despite initial response rates of the order of 50%, the
majority of patients will ultimately succumb to their disease
(Ozols, 1991). Although carboplatin is undoubtedly able to
offer patients a more acceptable level of morbidity compared
to cisplatin, the results of both randomised and cross-over
studies indicate that the two agents are effective against
essentially the same population of tumours (Gore et al., 1989;
Mangioni et al., 1989; Eisenhauer et al., 1990; Advanced
Ovarian Trialists Group, 1991). Therefore, there remains an
unequivocal need to discover and develop additional drugs
which possess activity against cisplatin/carboplatin-resistant
tumours.
There is now a general consensus that cisplatin exerts its
cytotoxic effects through binding to DNA to produce a
variety of cross-links; both intra- and inter-strand (e.g.
Roberts et al., 1986 for a review). Studies of platinum-
induced tumour resistance have generally utilised in vitro
tumour cell line models, both murine (e.g. L1210; Burchenal
et al., 1977 or P388; Waud et al., 1991) or human tumours
such as ovarian (e.g. Behrens et al., 1987) or lung (Hospers et
al., 1988). Typically, pairs of sensitive and cisplatin-acquired
resistant variant cell lines have been established where resis-
tance has been generated in vitro by exposure to high concen-
trations of cisplatin over many months. These investigations
indicate that the basis for platinum resistance is often multi-
focal, involving one or more of decreased accumulation,
increased intracellular detoxification (through glutathione or
metallothionein) or increased DNA repair (Andrews &
Howell, 1990a; McKeage et al., 1991, for reviews). The
clinical relevance of these in vitro based findings, however, is
largely untested.
To date, there has been relatively little study of platinum
resistance in the in vivo setting, either involving primary
human tumour tissue or murine-based tumour models. While
some mechanistic studies of drug resistance (e.g. the occur-
rence of multidrug resistance) have been successfully carried
out in patients, the routine usage of primary human tissue
can be problematic. Commonly, only a small biopsy from a
heterogeneous tumour is available; results may be difficult to
interpret due to patient treatment with additional non-
platinum drugs; there is generally not a continual, depend-
able, supply (especially within patients before and after treat-
ment); and the definition of resistance in the clinical setting is
largely subjective. An appropriate alternative, which offers a
continual supply of human tumour tissue, might be the use
of human tumour xenografts grown in athymic nude mice.
Our platinum-based drug discovery programme is aimed at
developing drugs capable of circumventing cisplatin/carbo-
platin resistance. To assist in this objective, we have estab-
lished panels of in vitro (Hills et al., 1989) and in vivo
(Harrap et al., 1990) human ovarian carcinoma lines.
Furthermore, these panels exhibit an excellent in vitro vs in
vivo correlation in cisplatin sensitivity/response (Kelland et
al., 1992b). In this study, we report on the establishment of in
vivo models of platinum acquired resistance using six human
ovarian carcinoma xenografts. Resistance has been generated
to cisplatin (three lines), carboplatin (one line), iproplatin
(three lines) and tetraplatin (one line) either by treatment in
vivo or (for one line) through exposure in vitro and subse-
quent transfer to mice. We have used these models, including
the one pair of lines available both in vitro and in vivo, to
determine cross-resistance profiles to these platinum agents.
Materials and methods
Human tumour xenografts
Six parent human ovarian carcinoma tumour lines have been
used in this study; HX/110, PXN/87, PXN/94, PXN/95,
PXN/100 and PXN/109T/C. Their establishment, charac-
terisation and calibration against cisplatin, carboplatin,
iproplatin and tetraplatin has been described previously
(Harrap et al., 1990). HX/110 and PXN/87 were established
from previously untreated patients, PXN/94 and PXN/95
from patients previously treated with carboplatin and ifos-
famide and PXN/100 and PXN/109T/C from patients treated
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with regimes containing both cisplatin and carboplatin.
Implants were made subcutaneously (s.c.) to one strain of
female nude (nu/nu) mice (age 6-8 weeks) under halothane
anaesthesia using a 2 mm diameter fragment. Animals were
housed in negative pressure, flexible film isolators and main-
tained on Labsure 21% protein diet (irradiated at 2.5 Mrads)
with access to autoclaved tapwater ad libitum.
Derivation ofplatinum acquired resistant lines
HX/IIO, PXN/87, PXN/94, PXN/95 and PXN/IOO Orig-
inally a group of six mice bearing tumours of 8-1O mm
diameter were treated with the selected platinum drug
(q7days schedule for at least 4 weeks). Drugs, generally at
maximum tolerated doses, were administered i.p. in saline.
Thereafter, the tumour exhibiting the least response was
passaged into new recipients (six animals) and mice bearing
resulting tumours treated in a manner analogous to clinical
practice (e.g. whenever the tumour began to regrow, pro-
viding no clinical signs of toxicity from the previous course
of treatment were apparent). Treatments were repeated (with
tumours being passaged into new mice if tumours became
excessively large) until one tumour (where growth delays
were no longer achievable) was selected for calibration.
PXN/109T/C This xenograft line was derived from the con-
tinuous in vitro cell line, CHI (Hills et al., 1989) by s.c.
injection of 5 x 106 cells. A cisplatin acquired resistant
xenografted subline (PXN/109T/CC) was similarly derived
from a companion cisplatin-resistant cell line (CHlcisR),
where CH1 was exposed to increasing concentrations of cis-
platin up to 1 tLM over a 15 month period. Further establish-
ment and characterisation details of CH1cisR have been
described previously (Kelland et al., 1992c).
Tissue storage, karyotyping, histopathology
All tumour material was stored between passage under liquid
nitrogen. Karyotypic analysis was performed on both parent
and resistant sublines by the administration of colcemid
(1 mg kg-') to animals for 3 h. Tumours were then excised,
chopped, homogenised and cells swollen in hypotonic KCI
(0.075 M) for 20 min. Cells were then fixed with ice-cold
glacial acetic acid:methanol (1:3), and dropped onto slides.
Spreads were air dried and stained with 5% Giemsa for
10 min. Histological sections were prepared by fixing
tumours in modified Methacarn and staining sections with
haematoxylin and eosin.
Platinum agents
The platinum-containing agents cisplatin (CDDP, Neoplatin,
cis-Diamminedichloroplatinum (II)), carboplatin {JM8, CB-
DCA, Paraplatin, cis-Diammine-l,l-cyclobutane-dicarboxy-
lato-platinum (II)) and iproplatin (JM9, CHIP, cis-dichloro-
trans-dihydroxo-cis bis (isopropylamine) platinum (IV)) were
synthesised by and obtained from the Johnson Matthey
Technology Centre (Reading, Berkshire). Tetraplatin {Orma-
platin, NSC 363812, trans-d,l 1,2-diaminocyclohexane tetra-
chloroplatinum (IV)) was kindly provided by Dr M.
Wolpert-Defilippes (NCI, Bethesda, MD, USA).
Assessment ofchemosensitivity
In order to maintain levels of resistance, animals bearing
established resistant lines were treated with the maximum
tolerated dose (MTD) of the appropriate agent at each
passage. Maximum tolerated doses, (CDDP, 8 mg kg-';
CBDCA, 100mgkg-'; CHIP, 60mgkg-1; tetraplatin, 8mg
kg-') were administered intraperitoneally (i.p.) in saline;
doses were determined from previously described experiments
(Harrap et al., 1990; Kelland et al., 1992b). Following the
maintenance dose, at least 10 days were allowed to elapse
before tumours were passaged for subsequent chemo-
sensitivity assessment.
Chemosensitivity was then assessed as described previously
(Harrap et al., 1990; Kelland et al., 1992b). Briefly, mice
bearing comparably-sized tumours (approximately 8 mm
diameter) were randomised into treatment groups (six
animals), or control groups (ten animals). Drugs were
administered by i.p. injection in saline at the MTD, on day 0
and thereafter, on days 7, 14 and 21. Tumour volumes (V)
were then calculated from weekly caliper-derived diameter
measurements according to the formula: V = a x b2 x 11/6
(where (a) is the longest diameter and (b) the next longest
diameter at right angles to (a), and volumes then normalised
to the volume at the start of treatment (day 0).
As previously (Harrap et al., 1990; Kelland et al., 1992b),
experiments were analysed by two methods: (1) 28 day T/C;
the ratio of the mean relative tumour volume of treated, to
that of control groups on day 28 post-treatment and, for two
of the lines, (2) growth delay; the difference in the time taken
for control vs treated tumours to double their volume. The
28-day post-treatment time was chosen since it represented
an ethically acceptable duration of survival for all untreated
control animals. From the growth delay data, specific growth
delay values (SGD) (an estimate of the number of volume
doubling times by which growth is delayed) have been deter-
mined according to published methods (Steel et al., 1983).
Determination ofresistancefactors in CHJ/CHJcisR
These cell lines were grown in Dulbecco's Modified Eagle's
Medium (DMEM) containing 10% heat inactivated (55°C,
30 min) foetal calf serum and 50 1tgml-' gentamicin,
2.5fg.ml-' amphotericin B, 2 mM L-glutamine, 10Igml-l
insulin and 0.5 jig.ml-' hydrocortisone in 10% C02/90% air
as described previously (Kelland et al., 1992c).
Platinum agents were dissolved as for the xenograft
experiments and cytotoxicity assessed following 96 h drug
exposure by the sulforhodamine B (SRB) assay as previously
described (Mistry et al., 1991). Resistance factors were deter-
mined as ratios of the IC50 values for the pair of cell lines.
Results
A total of eight acquired resistant lines, were successfully
established. Lines have been assigned according to the agent
used to generate resistance; C = cisplatin (PXN/87C, PXN/
95C, PXN/109T/CC), P = carboplatin (Paraplatin) (HX/
1 lOP), I = iproplatin (PXN/871, PXN/941, PXN/951) and
T = tetraplatin (PXN/1OOT). Seven of these were established
by treatment of tumours in vivo while PXN/109T/CC was
derived from the companion cell line, CHlcisR. The doses
used and the times taken to generate resistance are shown in
Table I. The average total time for resistance to be estab-
lished in vivo was 88 weeks; a similar time (70 weeks) was
observed for the in vitro derived CHlcisR (corresponding to
the PXN/109T/CC) cell line. It should be noted that for
HX/llOP and PXN/87C, the doses used to establish resis-
tance were a little higher than our above quoted MTD values
(while, for tetraplatin, a lower dose was used).
TableI Dosesand timetaken togenerate platinum acquired resistance
for each of the eight lines
Time (weeks)
Dose level for resistance
Tumour Agent (mg kg-') to develop
HX/1 0OP Carboplatin 120 115
PXN/87C Cisplatin 12 119
PXN/871 Iproplatin 60 88
PXN/941 Iproplatin 60 85
PXN/95C Cisplatin 8 53
PXN/951 Iproplatin 60 50
PXN/100T Tetraplatin 4 106
PXN/109T/CC Cisplatina 1 lLMa 70a
aResistance developed in vitro.26 M. JONES et al.
Karyotypic analysis of the resistant lines showed them all
to be of human origin. Four (HX/1 lOP, PXN/87C, PXN/95C
and PXN/109T/CC) possessed histological characteristics
closely comparable to the tissue of origin. The remaining
four lines showed some differentiated characteristics; for
example, all three lines with derived resistance to iproplatin
(PXN/87I, PXN/941, PXN/951) showed an increase in glan-
dular structures with associated cystic dilatation when com-
pared to their respective parent tumours. Whereas PXN/100
was entirely of undifferentiated appearance, PXN/100T pos-
sessed some moderately differentiated glandular structures.
The percentage of murine stroma present in tumours was
quite variable both in sensitive and resistant sublines and
even within different tumours of the same passage. There was
no obvious change in the amount of stroma present after
continuous retreatment of xenografts in aging mice.
Tumour volume doubling times for parent and acquired
resistant tumours showed that, for four lines (HX/1 lOP,
PXN/109T/CC, PXN/95C and PXN/871) there was little
difference in doubling time compared to the parent tumours.
Values (in days ± s.d.) were HX/l 10, 6.6 ± 4 and HX/1 lOP,
7.9 ± 4.8; PXN109T/C, 8.6 ± 1.2 and PXN109T/CC, 7.2 ±
0.2; PXN/95, 17.7 ± 6.6 and PXN95C, 14.5 ± 0.2; PXN/87,
12.1 ± 9.3 and PXN/871, 12 + 1.1. Three appeared to grow
somewhat faster: PXN/941 7.5 ± 2.5 days compared to
17.5 ± 8.2 days for the parent line; PXN/951 8.5 ± 0.2 days
compared to 17.7 ± 6.6 days for the parent line and PXN/
lOOT 4.8 ± 1.8 days compared to 7.2 ± 3.2 days for the
parent line. One line, PXN/87C (24.2 ± 6.1 days) grew more
slowly than the parent (12.1 ± 9.3 days).
a
Cross-resistance profiles
Cross-resistance profile histograms for the eight acquired
resistant lines are shown in Figures 1 (a = HX/1 lOP;
b = PXN/941), 2 (a = PXN/87C and PXN/871; b = PXN/95C
and PXN95/I; c = PXN/1OOT) and 3 (a = PXN/109T/CC).
There were six animals in each treated group and ten con-
trols; typically T/C values showed a 30% variation from the
mean. Lines have been compared in terms of 28 day T/C
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Figure 1 Cross-resistance profile histograms to cisplatin, carbo-
platin, iproplatin and tetraplatin administered at optimal doses
and schedules in terms of 28 day T/C values for a HX/1 10 (solid
bars) vs HX/I lOP (open bars) and b PXN/94 (solid bars) vs




* PXN/100 T N-
0.2
0.1
Cisplatin Carboplatin Iproplatin Tetraplatin
Figure 2 Cross-resistance profile histograms to cisplatin, carbo-
platin, iproplatin and tetraplatin administered at optimal doses
and schedules in terms of28 days T/C values for a PXN/87 (solid
bars) vs PXN/87C (diagonal hatched bars) vs PXN/871 (horizon-
tal hatched bars) and b PXN/95 (solid bars) vs PXN/95C
(diagonal hatched bars) vs PXN/951 (horizontal hatched bars)
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a marked sensitivity (i.e. T/C<0.1) to the DACH-platinum
(IV) complex, tetraplatin. To date, it has not proven possible
to generate resistance to cisplatin or carboplatin in this
highly platinum-sensitive tumour (due primarily to drug-
induced complete tumour regression). Where resistance has
been derived to tetraplatin (PXN/1OOT) some degree of sen-
sitivity was retained by cisplatin (T/C of 0.04).
Since at least a 6 week gap occurred between the
maintenance dose of platinum drug and chemosensitivity
testing (i.e. while the tumour was transplanted into mice and
the tumours grew to 8-10 mm diameter) it is clear that
resistance is stable for at least 2 months. However, we have
not, as yet, conducted studies into the longer-term stability of
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Figure 3 Comparative in vivo and in vitro cross-resistance profile
histograms for a xenografted lines PXN/109T/C (solid bars) vs
PXN/109T/CC (diagonal hatched bars) and b cell lines CHI/
CHlcisR. In vivo data shown in terms of 28-day T/C values and
in vitro data in terms of resistance factors (IC50 CHlcisR/1C50
CH1); mean of three independent experiments.
Table II Chemosensitivity (in terms ofspecificgrowthdelayvalues) for
both parent and acquired resistant xenografts
Tumour Cisplatin Carboplatin Iproplatin Tetraplatin
HX/10 17.2 13.9 3.6 1.4
HX/110P 0.86 1.8 0.59 0.13
PXN/109T/C 15.2 5.1 5.9 0.64
PXN/109T/CC 0.51 2.7 2.1 1
PXN/109T/C) specific growth delay values have been deter-
mined. These are shown for all four agents in Table II.
Comparative in vitro cross-resistance data for PXN/109T/CC
are shown in Figure 3b.
The four lines with acquired resistance to the platinum (II)
agents cisplatin (PXN/87C, PXN/95C and PXN/109T/CC)
and carboplatin (HX/l lOP) showed a general cross-resistance
to the other agents studied (Figures 1-3). Moreover, for
PXN/109T/CC, a similar pattern of cross-resistance to car-
boplatin, iproplatin and tetraplatin was also observed with
the companion CH1/CHlcisR in vitro cell lines.
While two of the three lines with resistance to the platinum
(IV) agent, iproplatin (PXN/94I and PXN/87I) showed a
general cross-resistance to cisplatin and carboplatin, PXN/
951 retained a similar degree of sensitivity to cisplatin and
carboplatin as observed for its parent tumour. Also of
interest is the somewhat higher efficacy of tetraplatin to the
PXN94I and PXN/951 tumours relative to their parent lines.
Only one parent tumour line (PXN/100) exhibited a
We have attempted to generate resistance to the clinically
used platinum drugs cisplatin, carboplatin, iproplatin and
tetraplatin in a panel of tumours in a manner analogous to
clinical practice. Thus, rather than using the more traditional
laboratory approach of treating tumours (or, more com-
monly, exposing cell lines) to low then gradually escalating
doses (concentrations) of drug (e.g. Seeber et al., 1982;
Behrens et al., 1987) we have treated tumours throughout at
approximately maximum tolerated doses whenever animals
could tolerate further treatment. Moreover, rather than using
rapidly- growing murine tumour lines such as L1210 or P388
leukaemias (Burchenal et al., 1977; Schabel et al., 1983), or
Ehrlich Ascites tumour cells (Seeber et al., 1982), we have
used slower-growing cisplatin-responsive human ovarian car-
cinoma xenografts. Seven acquired resistant lines have been
generated by this approach; two to cisplatin, one to carbo-
platin, three to iproplatin and one to tetraplatin.
To date, clinical cross-over studies have been performed in
patients presenting with advanced ovarian carcinoma using
cisplatin vs carboplatin (Gore et al., 1989; Eisenhauer et al.,
1990) and cisplatin followed by iproplatin (Sessa et al., 1988;
Weiss et al., 1991). These cross-over studies strongly suggest
that all three agents essentially share cross-resistance with
each other. Our data using four xenografted lines with
derived resistance to cisplatin and carboplatin are reminiscent
of these clinical observations; cross-resistance being exhibited
to cisplatin/carboplatin and iproplatin.
Other reports of in vivo tumour models of cisplatin
acquired resistance are mainly murine-based (Ferrari et al.,
1989; Goddard et al., 1991), rat (Zeller et al., 1991), and two
involving human ovarian tumours (A2780, Rose & Basler,
1990, and 2008; Andrews et al., 1990b). In common with our
findings, the A2780/A278OcDDP models, where acquired
resistance was originally developed in vitro (Behrens et al.,
1987), also showed cross-resistance to carboplatin, iproplatin
and tetraplatin (Rose & Basler, 1990). In addition, cross-
resistance to these agents has been observed in other murine-
based cisplatin resistant tumours; the M5076 reticular cell
sarcoma (Ferrari et al., 1989), and the ADJ/PC6 plasma-
cytoma (Goddard et al., 1991).
The PXN/109T/C and cisplatin-resistant pair of xenografts
and the companion CHI and CHlcisR pair of in vitro cell
lines exhibited similar patterns ofcross-resistance to the other
platinum agents studied. We have also observed a strong
positive correlation in cisplatin response between eight in
vitro 'parent' human ovarian carcinoma cell lines and com-
panion xenografts (Kelland et al., 1992b). As previously
reported, CHlcisR is approximately 6-fold resistant to cis-
platin compared to CHI (Kelland et al.,1992c). It is apparent
that this relatively low level of resistance to cisplatin is
sufficient to reduce the specific growth delay observed in vivo
for the parent line by approximately 30-fold. Whilst, to date,
no mechanistic studies of resistance have been performed in
vivo, experiments using the companion cell lines suggest that
resistance in CHlcisR is probably due to an enhanced
removal of platinum-DNA adducts (Kelland et al., 1992c).
This is the first study we are aware of where resistance has
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been generated in vivo to the platinum (IV) agents iproplatin
and tetraplatin. There was some evidence of a different pat-
tern of cross-resistance being obtained compared to that
observed for the cisplatin/carboplatin resistant lines. In par-
ticular, in one iproplatin-resistant line (PXN/951), cisplatin
and carboplatin circumvented resistance; exhibiting a similar
level of response to that observed for the parent line. In
another tumour, PXN87I, cisplatin retained some activity. In
addition to the differences in cross-resistant data, the
platinum (IV) drugs also appeared to induce some differences
in tumour histology compared to cisplatin and carboplatin.
This was most notable for the PXN/87 and PXN/95 tumours
where resistance to cisplatin induced no change in histo-
logical appearance whereas resistance to iproplatin induced
changes consistent with increased tumour differentiation.
Tetraplatin is currently in phase I clinical trial (Christian et
al., 1991). It was selected for clinical trial based largely on its
ability to circumvent acquired cisplatin resistance in murine
L1210 leukaemia cells, both in vitro and in vivo (Burchenal et
al., 1977). In our previous studies using two murine tumour
models with acquired cisplatin resistance, the L1210 leuk-
aemia and the ADJ/PC6 plasmacytoma, tetraplatin was even
more active in the resistant L1210 than in the parent tumour
(thus confirming the published studies) but shared cross-
resistance with carboplatin and iproplatin in the ADJ/PC6
(Goddard et al., 1991). In the panel of human ovarian xeno-
grafts used herein, tetraplatin was markedly active (T/C of
<0.1) against only the highly platinum-sensitive PXN/100
line.
In summary, similarly to clinical cross-over studies, we
have observed shared cross-resistance between cisplatin,
carboplatin and iproplatin in four cisplatin or carboplatin-
acquired resistant tumours. There was some evidence that
generation of resistance to the platinum (IV) agents ipro-
platin (and to a lesser extent, tetraplatin) might induce a
different pattern of cross-resistance. Cisplatin appeared to
retain some activity in three of four such tumours. These in
vivo models of acquired platinum reistance provide a useful
addition to our repository of preclinical models (both human
and murine) to be used for the discovery of novel more
broad-spectrum platinum-based anticancer drugs. In partic-
ular, they complement our recently described in vitro models
of acquired resistance (Kelland et al., 1992a,b) and com-
panion in vitro and in vivo human ovarian carcinoma models
of intrinsic cisplatin resistance (Hills et al., 1989; Harrap et
al., 1990; Kelland et al., 1992a,b). Furthermore, these models
allow the opportunity to investigate further the biochemical
mechanisms responsible for the resistance of tumours to
cisplatin and whether, as has recently been suggested for the
murine EMT-6 tumour (Teicher et al., 1990), some
mechanisms only operate in vivo.
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